Manolescu Loredana, Temereanca Aura, Diaconu Carmen Cristina, Ruta Simona
Stefan S. Nicolau Institute of Virology, Bucharest, Romania.
Rom Biotechnol Lett. 2011 Aug;16(4):6439-6449.
As available data on HIV-1 strains from Romania indicate the prevalence of a particular subtype- F, not found in other European countries, we aimed at investigating the impact on drug susceptibility of mutations associated with drug resistance and their correlation with the virological and immune response to therapy. METHODS: 38 long term survivors, HIV-1 parenterally infected in childhood, with repeated virological failures, were genotyped for drug resistance and subtype determination. A phylogenetic tree of aligned reversetranscriptase sequences was built. RESULTS: 94.7% of all the patients'strains were subtype F1, clustering together with other Romanian and Angolan F1 strains. Despite the long and complex treatments, 15.8% of patients had wild type virus, 68.4% were fully susceptible to protease inhibitors, 47.3% to non-nucleoside reverstranscriptase inhibitors, 28.9% to nucleoside reverstranscriptase inhibitors. Only 13.2% were resistant to all antiretroviral drug classes. A significantly higher total number of mutations were encountered in severely immunosuppressed patients, who presented also major mutations in the protease gene (V82A, I54V, G48V) and the major M184V mutation associated with type 2 thymidine analogs mutations in reverstranscriptase gene. CONCLUSION: A good immune status seems to be associated with a low range of mutations, indicating the impact of immune restoration or preservation on the therapeutic success rate. The slower post-HAART progression of mutational pattern of HIV- 1 subtype F1 in long term survivors may also influence the viral replicative fitness, a fact that can explain its steady prevalence in Romania.
鉴于罗马尼亚的HIV-1毒株现有数据显示存在一种在其他欧洲国家未发现的特定亚型——F亚型,我们旨在研究与耐药性相关的突变对药物敏感性的影响及其与治疗的病毒学和免疫反应的相关性。方法:对38名童年期经肠道外感染HIV-1且反复出现病毒学失败的长期存活者进行耐药性基因分型和亚型测定。构建了经比对的逆转录酶序列的系统发育树。结果:所有患者毒株的94.7%为F1亚型,与其他罗马尼亚和安哥拉的F1毒株聚集在一起。尽管接受了长期且复杂的治疗,但15.8%的患者病毒为野生型,68.4%对蛋白酶抑制剂完全敏感,47.3%对非核苷类逆转录酶抑制剂敏感,28.9%对核苷类逆转录酶抑制剂敏感。只有13.2%对所有抗逆转录病毒药物类别耐药。在严重免疫抑制的患者中遇到的突变总数显著更高,这些患者在蛋白酶基因中还存在主要突变(V82A、I54V、G48V)以及与逆转录酶基因中2型胸苷类似物突变相关的主要M184V突变。结论:良好的免疫状态似乎与低突变范围相关,表明免疫恢复或保存对治疗成功率的影响。长期存活者中HIV-1 F1亚型在高效抗逆转录病毒治疗(HAART)后突变模式进展较慢也可能影响病毒复制适应性,这一事实可以解释其在罗马尼亚的稳定流行率。